177 related articles for article (PubMed ID: 2731184)
1. Antibody response after immunization with the gangliosides GM1, GM2, GM3, GD2 and GD3 in the mouse.
Livingston PO; Ritter G; Calves MJ
Cancer Immunol Immunother; 1989; 29(3):179-84. PubMed ID: 2731184
[TBL] [Abstract][Full Text] [Related]
2. Approaches to augmenting the immunogenicity of the ganglioside GM2 in mice: purified GM2 is superior to whole cells.
Livingston PO; Calves MJ; Natoli EJ
J Immunol; 1987 Mar; 138(5):1524-9. PubMed ID: 3805726
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity of melanoma-associated gangliosides in cancer patients.
Tai T; Cahan LD; Tsuchida T; Saxton RE; Irie RF; Morton DL
Int J Cancer; 1985 May; 35(5):607-12. PubMed ID: 3997282
[TBL] [Abstract][Full Text] [Related]
4. Antibody responses to ganglio-series gangliosides in different strains of inbred mice.
Kawashima I; Nakamura O; Tai T
Mol Immunol; 1992 May; 29(5):625-32. PubMed ID: 1584231
[TBL] [Abstract][Full Text] [Related]
5. Differential roles of gangliosides in malignant properties of melanomas.
Ohmi Y; Kambe M; Ohkawa Y; Hamamura K; Tajima O; Takeuchi R; Furukawa K; Furukawa K
PLoS One; 2018; 13(11):e0206881. PubMed ID: 30462668
[TBL] [Abstract][Full Text] [Related]
6. Vaccines containing purified GM2 ganglioside elicit GM2 antibodies in melanoma patients.
Livingston PO; Natoli EJ; Calves MJ; Stockert E; Oettgen HF; Old LJ
Proc Natl Acad Sci U S A; 1987 May; 84(9):2911-5. PubMed ID: 3472242
[TBL] [Abstract][Full Text] [Related]
7. Characterization of IgG and IgM antibodies induced in melanoma patients by immunization with purified GM2 ganglioside.
Livingston PO; Ritter G; Srivastava P; Padavan M; Calves MJ; Oettgen HF; Old LJ
Cancer Res; 1989 Dec; 49(24 Pt 1):7045-50. PubMed ID: 2582446
[TBL] [Abstract][Full Text] [Related]
8. Expression of the gangliosides GM3, GD3 and GD2 in tissue sections of normal skin, naevi, primary and metastatic melanoma.
Hersey P; Jamal O; Henderson C; Zardawi I; D'Alessandro G
Int J Cancer; 1988 Mar; 41(3):336-43. PubMed ID: 3346097
[TBL] [Abstract][Full Text] [Related]
9. Approaches to augmenting the immunogenicity of melanoma gangliosides: from whole melanoma cells to ganglioside-KLH conjugate vaccines.
Livingston PO
Immunol Rev; 1995 Jun; 145():147-66. PubMed ID: 7590824
[TBL] [Abstract][Full Text] [Related]
10. Preparation and properties of antibodies to GD3 and GM1 gangliosides.
Kundu SK; Marcus DM; Veh RW
J Neurochem; 1980 Jan; 34(1):184-8. PubMed ID: 6778957
[TBL] [Abstract][Full Text] [Related]
11. Serum anti-ganglioside IgM antibodies in soft tissue sarcoma: clinical prognostic implications.
Perez CA; Ravindranath MH; Soh D; Gonzales A; Ye W; Morton DL
Cancer J; 2002; 8(5):384-94. PubMed ID: 12416896
[TBL] [Abstract][Full Text] [Related]
12. Cell surface accessibility of individual gangliosides in malignant melanoma cells to antibodies is influenced by the total ganglioside composition of the cells.
Lloyd KO; Gordon CM; Thampoe IJ; DiBenedetto C
Cancer Res; 1992 Sep; 52(18):4948-53. PubMed ID: 1516051
[TBL] [Abstract][Full Text] [Related]
13. Ganglioside antigens in tissue sections of skin, naevi, and melanoma--implications for treatment of melanoma.
Hersey P
Cancer Treat Res; 1991; 54():137-51. PubMed ID: 1673856
[TBL] [Abstract][Full Text] [Related]
14. Differential expression of gangliosides and galactolipids in fetal human oligodendrocytes and astrocytes in culture.
Satoh JI; Tai T; Kim SU
Brain Res Dev Brain Res; 1996 May; 93(1-2):172-81. PubMed ID: 8804704
[TBL] [Abstract][Full Text] [Related]
15. Selection of tumor antigens as targets for immune attack using immunohistochemistry: I. Focus on gangliosides.
Zhang S; Cordon-Cardo C; Zhang HS; Reuter VE; Adluri S; Hamilton WB; Lloyd KO; Livingston PO
Int J Cancer; 1997 Sep; 73(1):42-9. PubMed ID: 9334808
[TBL] [Abstract][Full Text] [Related]
16. Fine specificity of natural killer T cells against GD3 ganglioside and identification of GM3 as an inhibitory natural killer T-cell ligand.
Park JE; Wu DY; Prendes M; Lu SX; Ragupathi G; Schrantz N; Chapman PB
Immunology; 2008 Jan; 123(1):145-55. PubMed ID: 18154620
[TBL] [Abstract][Full Text] [Related]
17. Two human monoclonal antibodies reacting with the major gangliosides of human melanomas and comparison with corresponding mouse monoclonal antibodies.
Furukawa K; Yamaguchi H; Oettgen HF; Old LJ; Lloyd KO
Cancer Res; 1989 Jan; 49(1):191-6. PubMed ID: 2908845
[TBL] [Abstract][Full Text] [Related]
18. Aberrant expression of gangliosides in human renal cell carcinomas.
Hoon DS; Okun E; Neuwirth H; Morton DL; Irie RF
J Urol; 1993 Dec; 150(6):2013-8. PubMed ID: 8230555
[TBL] [Abstract][Full Text] [Related]
19. Induction of antibodies against GD3 ganglioside in melanoma patients by vaccination with GD3-lactone-KLH conjugate plus immunological adjuvant QS-21.
Ragupathi G; Meyers M; Adluri S; Howard L; Musselli C; Livingston PO
Int J Cancer; 2000 Mar; 85(5):659-66. PubMed ID: 10699946
[TBL] [Abstract][Full Text] [Related]
20. Production of monoclonal antibodies directed to Hanganutziu-Deicher active gangliosides, N-glycolylneuraminic acid-containing gangliosides.
Watarai S; Kushi Y; Shigeto R; Misawa N; Eishi Y; Handa S; Yasuda T
J Biochem; 1995 May; 117(5):1062-9. PubMed ID: 8586620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
